Home › Education › Peptide Therapy Safety
EducationPeptide Therapy Safety. What the Research Says
An evidence-based review of what is known about peptide therapy safety, which compounds have the strongest safety profiles, and how physician oversight affects risk.
PSI is an independent research platform. This page is educational and does not constitute medical advice. Consult a licensed physician before beginning any peptide therapy protocol.
Safety varies by compound
There is no single answer to whether peptide therapy is safe because peptides are not a single category of treatment. Each compound has its own mechanism, evidence base, and risk profile. Grouping them together for safety purposes is like asking whether "medications" are safe.
PSI assigns evidence levels to every compound. Higher evidence levels generally correlate with more safety data, but not always with lower risk. FDA-approved GLP-1 agonists have extensive safety data and known side effect profiles. Experimental peptides with limited human data carry unknown long-term risk.
Compounds with the strongest safety data
Semaglutide and tirzepatide (FDA Approved), the most extensively studied peptides in clinical use. Large-scale trials involving tens of thousands of participants. Known side effects are well-characterized, primarily gastrointestinal.
Sermorelin (Human Trials), FDA-approved history for GH deficiency. Long clinical track record. Side effects generally mild, injection site reactions, flushing, headache.
BPC-157 (Human Trials), strong animal safety data, early human data. No large-scale human trials yet. Considered low-risk by many practitioners but long-term human data is limited.
The compounding pharmacy question
Most peptides used in clinical practice outside of FDA-approved drugs are sourced from compounding pharmacies. Legal 503A and 503B compounding pharmacies operate under pharmacy board oversight, but their products do not undergo FDA pre-market approval. Quality varies. A physician who sources from accredited pharmacies with documented third-party purity testing meaningfully reduces this risk.
How physician oversight changes the risk profile
The single largest safety variable in peptide therapy is not the compound, it is whether a qualified physician is managing the protocol. Baseline labs, dose titration, monitoring for adverse effects, and sourcing decisions all depend on physician competence and diligence. This is the primary reason PSI's physician directory applies a strict vetting standard.
Red flags to watch for
Be cautious of any provider who:
- , Does not require baseline labs before starting a protocol
- , Cannot name the compounding pharmacy they use
- , Prescribes without a consultation or health history review
- , Makes guarantees about outcomes
- , Cannot explain the mechanism of the compounds they prescribe